Navigation Links
Nativis Announces Publication of Study in Patients with Recurrent Glioblastoma (rGBM)
Date:12/18/2018

Nativis, Inc., a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of an early feasibility study in CNS Oncology suggesting that the Nativis Voyager device is safe for treatment of rGBM.

The publication of the study, An Early Feasibility Study of the Nativis Voyager® Device in Patients with Recurrent Glioblastoma: First Cohort in US, may be viewed HERE or on the Nativis web site.

“We are excited to have this publication accepted by CNS Oncology in conjunction with our internationally recognized clinical trial partners, led by Charles Cobbs, MD and Santosh Kesari, MD PhD,” stated Chris Rivera, Nativis Chief Executive Officer. “The data in this early feasibility study not only suggest that the Nativis Voyager device is safe for the treatment of rGBM, but also that further studies to explore clinical utility are warranted.”

The Nativis Voyager produces ultra-low radio frequency energy (ulRFE®) intended to induce a biologic response in solid tumors, such as rGBM. The ulRFE cognate is created by measuring and recording the oscillating magnetic field produced by molecules in solution. The recorded cognate is then used to reproduce the recorded magnetic field using an electromagnetic coil worn externally on the head by the patient.

“Nativis is grateful to our clinical partners, patients, and their families in this effort to develop an effective treatment for one of the most difficult diseases to treat known to medical science.” Rivera went on to state, “Without the efforts of our dedicated and extraordinary clinical partners, our patients and their families would have fewer hopes to address the devastating effects of rGBM.”

Rivera concluded, “We are looking forward to obtaining data from this ongoing clinical study for treatment of rGBM, with the expectation of producing safety and clinical utility results that are encouraging for our patients and their families.”

About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of medical conditions, as well as to veterinary medicine and non-medical applications. Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often results in poor outcomes and devastating side effects. Additional pre-clinical work is focused on exploring new applications in other oncology settings and pain management. The Nativis Voyager system is an investigational medical device, limited by United States law to investigational use only.

Media Contact:
Dennis Kroft
dkroft(at)nativis(dot)com
201-602-8354

Read the full story at https://www.prweb.com/releases/nativis_announces_publication_of_study_in_patients_with_recurrent_glioblastoma_rgbm/prweb15991523.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Nanomedical Diagnostics Announces Office Move to Accommodate Company Growth
2. Urological Associates of Southern Arizona Announces Dr. Kenneth Choi’s Designation as UroLift® Center of Excellence
3. Fastec Imaging Announces OEM Partner Program
4. EARTHRES Adds to Executive Team - Announces New Chief Operating Officer
5. Cloudponics Announces Holiday Discount For Leading Product, GroBox
6. Immuno-Oncology 360° (IO360°) NYC Gathering Announces Keynotes for the 5th Annual Event
7. FDAnews Announces — Early Bird Pricing Ends on Nov. 8 for Emerging Trends in Medical Device Regulation and Quality, Dec. 6, 2018, Washington, DC
8. Karius Announces the Clinical Investigator Award for Applied Pediatric Infectious Disease Genomics
9. Myoscience Announces Commercial Release of Nerve Stim Enabled iovera° Smart Tip
10. Slone Partners, Where People Are Our Science®, Announces Insights: Scientific Healthcare Investing 2018 Panel Event With Leaders In The Investment Community
11. Ajinomoto Health & Nutrition's Amino Acid Division Announces Price Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2019)... ... , ... R121 solidifies its place within The Planet Group ... with the name change, this rebranding includes a comprehensive redesign of the company’s ... brand that blended our core foundation of genuine ‘one-to-one’ relationships with Planet’s global ...
(Date:8/19/2019)... N.J. (PRWEB) , ... August 19, 2019 , ... ... have characterized tissues through the use of ultra-thin two dimensional slices which are ... can be highly limited for complex tissues and complicated features such as vasculature ...
(Date:8/14/2019)... ... August 14, 2019 , ... An upcoming episode ... in microbiome therapeutics are helping to promote normal immune function in order to ... will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops microbiome therapeutics in ...
Breaking Biology News(10 mins):
(Date:8/29/2019)... (PRWEB) , ... August 29, 2019 , ... ... year to teach in the Sustainable Medicines in Africa program, which includes a ... take place in Arusha, Tanzania September 2nd through 13th, 2019. Topics to ...
(Date:8/23/2019)... Wis. (PRWEB) , ... August 22, 2019 , ... The ... some of the most harmful germs and pathogens on hard surfaces including E. Coli, ... leaves behind no chemical residues. For more information, visit the product page at rovingblue.com ...
(Date:8/14/2019)... ... August 13, 2019 , ... Chata ... phases for QC laboratories. After gaining a few significant clients, Lifecycle purchased the ... a valued supplier of manufacturing processing solutions, including reagents for tissue processing. Chata ...
(Date:8/6/2019)... FARMINGTON, Conn. (PRWEB) , ... August 06, 2019 ... ... that develops tools for characterizing microbiome populations down to the strain level, has ... Biome’s microbiome kits and other products to companies and research organizations in Australia, ...
Breaking Biology Technology: